Diabetes: Medtronic joins $44m round for Semma Therapeutics

Medtronic gets in on a $44 million Series A round for Semma Therapeutics, which is developing a cell therapy-device treatment for Type 1 diabetes.

Harvard University, Medtronic, Semma Therapeutics

News Well, Diabetes, Drug-Device Combinations, Funding Roundup, Stem Cells

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1LYrTD6